$
0.000
0.000(0.000%)
  • Overview
  • Forecast
  • Valuation

OVID Relative Valuation

OVID's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, OVID is overvalued; if below, it's undervalued.

Historical Valuation

No Data

Competitors Valuation Multiple

The average P/S ratio for OVID's competitors is 18.74, providing a benchmark for relative valuation. Ovid Therapeutics Inc Corp (OVID) exhibits a P/S ratio of 91.22, which is 386.83% above the industry average. Given its robust revenue growth of -12.16%, this premium appears unsustainable.

FAQ

arrow icon

Is Ovid Therapeutics Inc (OVID) currently overvalued or undervalued?

Ovid Therapeutics Inc (OVID) is now in the Fair zone, suggesting that its current forward PS ratio of 91.22 is considered Fairly compared with the five-year average of 448.18. The fair price of Ovid Therapeutics Inc (OVID) is between 0.05 to 1.17 according to relative valuation methord.
arrow icon

What is Ovid Therapeutics Inc (OVID) fair value?

arrow icon

How does OVID's valuation metrics compare to the industry average?

arrow icon

What is the current P/B ratio for Ovid Therapeutics Inc (OVID) as of May 20 2025?

arrow icon

What is the current FCF Yield for Ovid Therapeutics Inc (OVID) as of May 20 2025?

arrow icon

What is the current Forward P/E ratio for Ovid Therapeutics Inc (OVID) as of May 20 2025?

arrow icon

What is the current Forward P/S ratio for Ovid Therapeutics Inc (OVID) as of May 20 2025?